Merck Reports observational Data for Cabotegravir in Beta-thalassemia

Merck today announced observational results for cabotegravir in patients with beta-thalassemia. The study demonstrated that cabotegravir achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of beta-thalassemia and support the continued development of cabotegravir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.